Abstract Number: 1794 • ACR Convergence 2023
The Role of the Deubiquitinase ZRANB1/TRABID in Inflammation and Bone Formation in Spondyloarthritis
Background/Purpose: Inflammation and new bone formation are important disease mediators in ankylosing spondylitis (AS). Recent studies in mice show that the deubiquitinase molecule TRABID epigenetically…Abstract Number: 0520 • ACR Convergence 2023
How Do Early Disease Activity and Early Clinical Response Associate with Long-Term Outcomes with Ixekizumab in Radiographic Axial Spondyloarthritis?
Background/Purpose: The ASAS-EULAR recommendations for the management of axial spondyloarthritis (axSpA) advise that a patient be assessed for biological disease-modifying anti-rheumatic drug (bDMARD) treatment response…Abstract Number: 1032 • ACR Convergence 2023
“Not of Your Ethnicity”: A Qualitative Study Exploring Diverse Patient Experiences in Axial Spondyloarthritis (axSpA)
Background/Purpose: Axial spondyloarthritis (axSpA) can result in significant morbidity. Existing studies suggest functional impairment and inflammation may be worse in Black and Latine patients. However,…Abstract Number: 1403 • ACR Convergence 2023
MRI-defined Sacroiliitis in First Degree Relatives of Ankylosing Spondylitis Patients
Background/Purpose: Sacroiliitis is a main radiographic finding in axial spondyloarthritis (axSpA) - the inflammatory rheumatic disease with a strong genetic background. The aim of this…Abstract Number: 1854 • ACR Convergence 2023
What Is Our Regional Delay to Diagnosis in Patients with Axial Spondyloarthropathy – Are We Hitting the Target? Data from a Multi-centre UK Patient Cohort
Background/Purpose: Due to the insidious onset of axial spondyloarthritis (AxSpA), there is often a significant delay to diagnosis. The average delay to diagnosis in the…Abstract Number: 0521 • ACR Convergence 2023
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies
Background/Purpose: The clinical manifestations of axial spondyloarthritis (axSpA) limit physical function and work productivity, posing an economic burden to patients (pts) and society.1 Bimekizumab (BKZ),…Abstract Number: 1209 • ACR Convergence 2023
The Role of Kinesiophobia on Ankylosing Spondylitis Disease Activity, Exercise Habits, and Quality of Life
Background/Purpose: Patients with Ankylosing Spondylitis (AS) consistently report exercise frequencies that are lower than healthy controls and ACSM/EULAR recommended frequencies; even though exercise has consistently…Abstract Number: 1404 • ACR Convergence 2023
Factor H-related protein-5 Exacerbates Pathological Bone Formation of Ankylosing Spondylitis
Background/Purpose: The complement factor H-related protein-5 (FHR-5), a member of the human factor H protein family, enhances complement activation. The influence of complement activation on…Abstract Number: 1860 • ACR Convergence 2023
Evaluation of the Receipt of Adequate Pharmacological and Psychological Treatment for Incident Depression and Anxiety in Individuals Living with Inflammatory Arthritis
Background/Purpose: To describe patterns of pharmacological and psychological treatment and evaluate the receipt of minimally adequate treatment for incident depression and anxiety in individuals with…Abstract Number: 0525 • ACR Convergence 2023
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Background/Purpose: In patients (pts) with axial spondyloarthritis (axSpA), tumor necrosis factor inhibitors (TNFi) are the usual first line biologic treatment, yet many pts may experience…Abstract Number: 1349 • ACR Convergence 2023
Paternal Effects of Anti-TNFs in Inflammatory Arthritis
Background/Purpose: Inflammatory arthritis is a group of rheumatic diseases characterized by the inflammation of joints with systemic manifestations: psoriatic arthritis (PsA), rheumatoid arthritis (RA), and…Abstract Number: 1405 • ACR Convergence 2023
Diagnostic Delay of Axial Spondyloarthritis in African American Patients
Background/Purpose: The identification of axial spondyloarthritis (axSpA) remains challenging. The initial presentation is not always immediately apparent as an inflammatory disease, potentially leading to years…Abstract Number: 1892 • ACR Convergence 2023
Sacroiliac Bone Marrow Oedema on Postpartum MRI Does Not Result in Significant SpA-like Structural Lesions: Results of a 5-year Follow-up Study
Background/Purpose: Sacroiliac bone marrow oedema (BMO) on MRI, immediately after childbirth, has been observed in a large proportion of postpartum women and appears to be…Abstract Number: 0526 • ACR Convergence 2023
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Background/Purpose: Axial spondyloarthritis (axSpA) severely impairs physical function and health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in…Abstract Number: 1383 • ACR Convergence 2023
Long-term Association Between Physical Activity and Global Functioning in Patients with axSpA: Results of a 2 Year Prospective Study
Background/Purpose: To assess the longitudinal association between physical activity and global functioning in patients with axial spondyloarthritis (axSpA) and to identify the subtype of physical…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 62
- Next Page »